Receptor News and Research

RSS

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.

22 Oct 2018

ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced initial safety and preliminary anti-tumor activity from the FORWARD II expansion cohort assessing mirvetuximab soravtansine in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab).

22 Oct 2018

X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 antagonists to improve immune cell trafficking to treat cancer and rare disease, today announced results from a pilot study of X4P-001-IO in combination with Opdivo (nivolumab) in patients with clear cell renal cell carcinoma who are non-responsive to the anti-PD-1 checkpoint inhibitor Opdivo alone.

22 Oct 2018

Breast cancer survival could be extended with two new drug combinations

A new study has shown that a combination of drugs palbociclib, along with hormone therapy can significantly increase the survival among women with advanced breast cancer.

21 Oct 2018

Research provides insight into neurobiology of aggression and bullying

Duke-NUS researchers have discovered that a growth factor protein, called brain-derived neurotrophic factor, and its receptor, tropomyosin receptor kinase B affects social dominance in mice. The research has implications for understanding the neurobiology of aggression and bullying.

20 Oct 2018

Newly developed synthetic DNA molecule may one day be used as 'vaccine' for prostate cancer

Researchers from City of Hope, a world-renowned comprehensive cancer center and independent biomedical research institution, have developed a synthetic DNA molecule that is programmed to jump-start the immune system to eradicate genetically distinct types of prostate cancer.

19 Oct 2018

New statistical method estimates long- and short-term risk of recurrence of breast cancer in US women

A statistical method could fill the gaps in the U.S. cancer registry data to estimate the short- and long-term risk of recurrence of hormone receptor (HR)-positive and HR-negative breast cancers.

19 Oct 2018

High rate of non-adherence to hormonal therapy found among premenopausal early breast cancer patients

Nearly one in six premenopausal women being treated for early stage breast cancer do not adhere adequately to tamoxifen therapy after one year of treatment, potentially putting themselves at increased risk of recurrence and reduced survival, a French prospective study reports at ESMO 2018.

19 Oct 2018

A new approach identified to control Zika virus, dengue fever

Mosquitoes are the world's deadliest animals, killing thousands of people and causing millions of illnesses each year.

19 Oct 2018

Father’s exposure to nicotine may cause cognitive deficits in descendants

A father’s exposure to nicotine may cause cognitive deficits in his children and even grandchildren, according to a study in mice publishing on October 16 in the open-access journal PLOS Biology by Pradeep Bhide of Florida State University in Tallahassee and colleagues.

19 Oct 2018

Study shows close link between cytokine interleukin-1ß and obesity-promoted colon cancer

A new study describes the mechanistic relationship between the cytokine interleukin-1β, (IL-1β) and obesity, showing that when IL-1β levels are increased in obesity, IL-1 receptor signaling activates multiple pathways leading to colon cancer.

18 Oct 2018

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes - one of the nation's fastest growing chronic diseases.

17 Oct 2018

Purdue Pharma, Eisai announce positive topline results from Phase 3 study of lemborexant

Eisai Co., Ltd. and Purdue Pharma L.P. announced positive topline results from SUNRISE 2, a long-term Phase 3 efficacy and safety evaluation of lemborexant, an investigational agent for sleep-wake regulation currently being studied for the potential treatment of multiple sleep-wake disorders.

17 Oct 2018

Study of Nigerian breast cancer patients reveals prevalence of aggressive molecular features

A study comparing DNA and RNA data from Nigerian breast cancer patients to patients in a United States database found that certain aggressive molecular features were far more prevalent in tumors from Nigerian women than in black or white American women.

16 Oct 2018

Purdue researchers develop new chemical process to find better drug 'fits' for patients

When a medication doesn't "fit" the body quite right, the results can be devastating. Such is the case for thalidomide, which was prescribed in the 1950s and 1960s as a sedative or hypnotic, even for pregnant women.

16 Oct 2018

Research points to potential new treatment for hearing loss

Researchers have taken an important step toward what may become a new approach to restore the hearing loss. In a new study, out today in the European Journal of Neuroscience, scientists have been able to regrow the sensory hair cells found in the cochlea - a part of the inner ear - that converts sound vibrations into electrical signals and can be permanently lost due to age or noise damage.

15 Oct 2018

Receptor News and Research

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress

X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma

Breast cancer survival could be extended with two new drug combinations

Research provides insight into neurobiology of aggression and bullying

Newly developed synthetic DNA molecule may one day be used as 'vaccine' for prostate cancer

New statistical method estimates long- and short-term risk of recurrence of breast cancer in US women

High rate of non-adherence to hormonal therapy found among premenopausal early breast cancer patients

A new approach identified to control Zika virus, dengue fever

Father’s exposure to nicotine may cause cognitive deficits in descendants

Study shows close link between cytokine interleukin-1ß and obesity-promoted colon cancer

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

Purdue Pharma, Eisai announce positive topline results from Phase 3 study of lemborexant

Study of Nigerian breast cancer patients reveals prevalence of aggressive molecular features

Purdue researchers develop new chemical process to find better drug 'fits' for patients

Research points to potential new treatment for hearing loss

Modeling Non-Numerical Data in Systems Biology

Smoking genes do not trigger heavier drinking, shows research

Kent State professor receives grant to study role of oxytocin in the developing brain

Scientists work to speed regeneration and recovery of your sense of taste

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News